THRD reports Q1 net loss $7.9M; FDA clears THB335 IND; Phase 1 trial initiated

Third Harmonic Bio, Inc.

2024-Q1 EPS reported $0.20

Cash $262.8M as of Mar 31, 2024; expected to fund operations through at least 2026.
Net loss $7.9M for Q1 2024 vs $9.1M in Q1 2023; R&D expense $6.2M, G&A $5.1M.
FDA cleared IND for THB335 (oral KIT inhibitor); Phase 1 SAD/MAD trial initiated, results expected 1H 2025.
Leadership: Christopher Dinsmore CSO, Dennis Dean Chief Non-Clinical Dev Officer, Jennifer Dittman promoted to Chief Dev Ops Officer.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Third Harmonic Bio, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

issued a press release reporting the Company’s financial results for the first quarter ended March 31, 2024

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001193125-24-138910

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.